SCHEDULE: Affinity Asset Advisors Discloses 7.3% Stake in Forte Biosciences

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,011,890 shares, representing 7.3% of Forte Biosciences, Inc. common stock as of March 31, 2026.

Summary

• Affinity Asset Advisors, LLC, acting as the investment manager for Affinity Healthcare Fund, LP, and Michael Cho, the managing member of Affinity Asset Advisors, LLC, have filed a Schedule 13G.
• The filing indicates beneficial ownership of 1,011,890 shares of Forte Biosciences, Inc. common stock.
• This holding represents approximately 7.3% of the Issuer's outstanding common stock as of March 31, 2026.
• The shares are directly held by Affinity Healthcare Fund, LP, with Affinity Asset Advisors, LLC exercising sole voting and dispositive power.
• Michael Cho also holds sole voting and dispositive power over these shares by virtue of his role in the Adviser.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a disclosure of existing ownership without new strategic announcements or performance data.

Positives

• Significant ownership stake (7.3%) reported by a dedicated healthcare fund manager, suggesting strategic interest.
• Clear reporting of beneficial ownership and control, indicating transparency.

Risks

• The filing does not detail specific investment strategies or future intentions regarding the stake, leaving potential future actions open to speculation.
• Concentration of ownership by a single entity could lead to significant influence on corporate decisions, which may or may not align with other shareholders' interests.

Future Outlook

The filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Forte Biosciences, Inc.'s future performance or the Reporting Persons' future investment plans.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Affinity Asset Advisors' strategic interest in Forte Biosciences, Inc., a player in the biotechnology sector, which is characterized by high growth potential and significant research and development investment.

Stakeholder Impact

• Shareholders: The increased institutional ownership may signal confidence in the company, potentially influencing market perception. However, the specific intentions of the reporting persons are not detailed.
• Management and Board of Directors: The significant stake may lead to increased engagement or scrutiny from Affinity Asset Advisors, LLC.

Next Steps

• Monitoring of Forte Biosciences, Inc.'s performance and strategic developments.
• Potential future filings by Affinity Asset Advisors, LLC and Michael Cho if their ownership stake changes significantly.

Key Dates

Keywords

Forte Biosciences, Affinity Asset Advisors, Michael Cho, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management